Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

68 results about "Cyclosporins" patented technology

The cyclosporins are a group of macrolides isolated from fungi and used as immunosuppresant drugs, for example after transplant surgery. They are nonribosomal peptide synthesized by cyclosporin synthetase.

Cyclosporine formulations for use in patients undergoing cataract surgery

A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.
Owner:SUN PHARMACEUTICAL INDUSTRIES LTD

Stable cyclosporine ophthalmic formulation and manufacturing process thereof

The present invention relates to a stable nanomicellar ophthalmic formulation comprising cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle, wherein the stable nanomicellar ophthalmic formulation is made by a method comprising: a) mixing the hydrogenated 40 polyoxyl castor oil and the octoxynol-40, wherein the mixing produces a Mixture A comprising a water content of less than 3%; b) adding the cyclosporine to the Mixture A to form a Mixture B; and c) mixing the Mixture B with the aqueous vehicle, thereby forming the stable nanomicellar ophthalmic formulation.
Owner:SUN PHARMACEUTICAL INDUSTRIES LTD

Liposome drug carrier with mucosal adhesion and its preparation method and application

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.
Owner:SICHUAN UNIV

Self-assembled paclitaxel nano-drug combined with cyclosporin A as well as preparation method and application of self-assembled paclitaxel nano-drug

The invention discloses a cyclosporin A combined self-assembly paclitaxel nano-drug and a preparation method and application thereof, and belongs to the field of biological medicine, the cyclosporin A combined self-assembly paclitaxel nano-drug is a nano-particle which is composed of paclitaxel, cyclosporin A and zinc ions and has a regular rod-like morphology, and the particle size of the nano-particle is 1-10 micrometers. The self-assembled paclitaxel nano-drug is prepared by combining cyclosporin A on the basis of a zinc ion coordinated supramolecular self-assembly strategy, so that the stability of the nano-drug can be improved, the toxic and side effects are reduced, the killing effect on drug-resistant tumors is enhanced, the approximate biological safety is retained, and the drug-resistant tumors are prevented from being damaged. The invention provides a new thought for overcoming the current situation of drug resistance of paclitaxel, and has important research value and wide application prospect.
Owner:DONGGUAN SANHANG MILITARY CIVIL INTEGRATION INNOVATION RES INST

Use of pyridoxatin and related analogs for control of candida auris

Fungi are prolific producers of secondary metabolites and represent a rich and relatively untapped source for novel drug leads. Numerous successful therapeutics have derived from fungi, including penicillin, cephalosporin, statins, and cyclosporin. However, many promising classes of natural product are never developed into drugs because their chemical synthesis is complex or because the native organisms that naturally produce them, do so at impractically low levels. Pyridoxatins are a class of promising anti-fungal secondary metabolites produced by several naturally occurring strains filamentous fungi. The molecules have complex structures that impede straightforward chemical synthesis or analoging to increase efficacy. The disclosure herein details novel a novel use of pyridoxatin class molecules for the treatment of Candida auris and novel methods for the biosynthesis of pyridoxatins through fermentation of engineered microbes.
Owner:REPETTI PETER P +2

Fermenting cyclosporin a producing strain of fusarium solani and its use

The application belongs to the technical field of microorganisms, and particularly relates to a Fusarium solani strain for fermenting cyclosporin A, and further discloses application of the Fusarium solani strain for fermenting cyclosporin A. The application screens a Fusarium solani FIM-CS-66-69 strain for high-yield cyclosporin A by using an atmospheric pressure room temperature plasma mutagenesis technology, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a high yield, in a fermentation experiment, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a titer of 16551 ug / mL, the yield of cyclosporin A is greatly improved, and the content of homologues is low, so that the Fusarium solani FIM-CS-66-69 strain is more suitable for industrialized fermentation production.
Owner:FUJIAN INST OF MICROBIOLOGY

Method for recovering cyclosporin A crystallization mother liquor

The invention relates to a recovery method of cyclosporin A crystallization mother liquor, which comprises the following steps: carrying out previous treatment and impurity removal on the cyclosporin A crystallization mother liquor, carrying out primary crystallization with a polar solvent, carrying out secondary crystallization with a non-polar solvent, and finally carrying out crystal transformation and drying with the polar solvent to obtain a cyclosporin A finished product. According to the method, the residual cyclosporin A in the crystallization mother liquor is effectively purified, waste of the residual cyclosporin A in the crystallization mother liquor is avoided, the production cost of the cyclosporin A can be remarkably reduced, the method is suitable for industrial production, the product content reaches 98.5% or above, and the maximum single impurity content is within 0.7%.
Owner:NINGXIA TAISHENG BIOTECH CO LTD

Paecilomyces lilacinus and application thereof in production of cyclosporin C and in prevention and treatment of bemisia tabaci

This invention relates to the field of insect control, specifically to the Paecilomyces lilacinus strain XI-5, and the extraction and identification of crude toxins produced by secondary metabolites of Paecilomyces lilacinus strain XI-5. This invention confirms that the secondary metabolites of Paecilomyces lilacinus strain XI-5 produce cyclosporine C. Cyclosporine C has a stomach poison effect on adult whiteflies. Twenty-four hours after application, the LC50 concentration of cyclosporine C against adult whiteflies was 31.75 µg / ml; compared to the control group, the LC30 concentration of cyclosporine C resulted in a decrease in oviposition / fertility in female whiteflies.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY +1

Stable multiple dose cyclosporin water-in-oil emulsion compositions

The present invention relates to the field of pharmaceutical technology and relates to emulsion compositions comprising the active pharmaceutical ingredient Cyclosporin and the method of preparing this composition.
Owner:ARDI FARMA ILAC PAZARLAMA TICARET LTD SIRKETI

Composition for promoting hair growth and combined hair restorer prepared from composition

The invention provides a composition for promoting hair growth and a combined hair growth agent prepared from the composition, and belongs to the technical field of hair growth. The composition is mainly prepared from the saarcodon imbricatum polysaccharide and gamma-hydroxy-N-methyl-L-leucine 4-cyclosporin A (CsA-4-OH), and is prepared from the saarcodon imbricatum polysaccharide and the gamma-hydroxy-N-methyl-L- The sarcodon aspratus polysaccharide is polysaccharide with the molecular weight range of 10,000-30,000 Daltons and is obtained through specific extraction and purification processes, so that the special biological activity of the sarcodon aspratus polysaccharide is ensured. The composition disclosed by the invention shows a remarkable effect in the aspect of promoting proliferation of hair follicle stem cells, so that the composition can be used for increasing the hair growth speed and reducing the potential side effects of the modified cyclosporin A at the same time.
Owner:QILU HOSPITAL(QINGDAO) CHEELOO COLLEGE OF MEDICINE SHANDONG UNIV

Method for preparing salts of isocyclosporin A

The present invention belongs to the technical field of drug synthesis. In particular, the present invention relates to a method for preparing salts of isocyclosporin A, in particular a method for preparing salts of isocyclosporin A by transesterification of cyclosporin A.
Owner:DOMPE FARMACEUTICI SPA

Agent for improving infertility, recurrent miscarriage, and state of pregnancy

PendingUS20250255852A1Organic active ingredientsCyclic peptide ingredientsRecurrent miscarriagePregnancy
Provided is a medicine and a method for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring normal immune state. A medicine for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring a normal immune state, includes, as an active ingredient, a compound selected from the group consisting of: (i) a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:wherein the respective reference numerals are as described in the specification, (ii) a cyclosporine, and (iii) rapamycin or a derivative thereof.
Owner:YAMAGUCHI KOUSHI

Use of pulegone as an active ingredient in immunosuppressants

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.
Owner:HAINAN UNIV

Combination formulations containing heterocyclic subunit acetamide derivatives

The present disclosure provides a suspension-type eye drop having excellent redispersibility. More specifically, the present disclosure provides an aqueous-based suspension formulation containing a first component and a second component wherein the first component is (E)-2-(7-trifluoromethylchroman-4-subunit)-N-(7-hydroxy-5, 6, 7, 8-tetrahydronaphthalene-1-yl) acetamide, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof. And the second component comprises at least one component selected from the group consisting of diquafosol, cyclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof.
Owner:SENJU PHARMA CO LTD +1

Use of cyclosporine analogues for treating fibrosis

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.
Owner:ACHILLE LIFE SCIENCES LTD

Pharmaceutical composition and particles

The present invention provides a pharmaceutical composition which contains a population of cells, wherein the cells comprise cells that accumulate in an inflamed site and particles that are introduced into the cells and contain a bioabsorbable polymer and a drug, and the drug is cyclosporin or minoxidil.
Owner:ORCHARD BIO INC

Extracellular cyclophilin inhibitor and use thereof

The present invention belongs to the technical field of biomedicine, and specifically relates to an extracellular cyclophilin inhibitor and the use thereof, wherein the structural general formula of the extracellular cyclophilin inhibitor of the present invention is as shown in formula (I). According to the present invention, a group capable of reacting with sulfhydryl of cysteine at a specific site on blood albumin is extracted by means of a side chain of a new cyclosporin derivative, and a drug conjugate is rapidly formed after same enters the body, which can effectively restrict the drug to the extracellular area and form targeted inhibition of extracellular cyclophilin, thereby achieving the aim of treating diseases associated therewith.
Owner:PEKING UNIV SHENZHEN GRADUATE SCHOOL